Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 6/20 | 0.98 |
| ▸ | SLC18A2 | Q05940 | 4/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.98 |
| ▸ | HPGD | P15428 | 3/20 | 0.98 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.98 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.98 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.98 |
| ▸ | LMNA | P02545 | 2/20 | 0.98 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.98 |
| ▸ | HTR1A | P08908 | 2/20 | 0.98 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.98 |
| ▸ | DRD2 | P14416 | 2/20 | 0.98 |
| ▸ | HTR2C | P28335 | 2/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.98 |
| ▸ | MEN1 | O00255 | 1/20 | 0.98 |
| ▸ | MAPT | P10636 | 1/20 | 0.98 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.98 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.98 |
| ▸ | DRD1 | P21728 | 1/20 | 0.98 |
| ▸ | DRD4 | P21917 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ketanserin SCHEMBL29361038 | 0.99 | HTR2A (1.00) | HTR2ASLC18A2CYP3A4HPGDSLC6A3 | |
| Ketanserin SCHEMBL34294 | 0.99 | HTR2A (1.00) | HTR2ASLC18A2CYP3A4HPGDSLC6A3 | |
| Ketanserin SCHEMBL4862503 | 0.99 | HTR2A (1.00) | HTR2ASLC18A2CYP3A4HPGDSLC6A3 | |
| Ketanserin SCHEMBL2030457 | 0.98 | HTR2A (0.98) | HTR2ASLC18A2CYP3A4HPGDSLC6A3 | |
| Ketanserin SCHEMBL30028921 | 0.98 | HTR2A (0.98) | HTR2ASLC18A2CYP3A4HPGDSLC6A3 | |
| Ketanserin SCHEMBL5614705 | 0.96 | HTR2A (0.94) | HTR2ASLC18A2CYP3A4HPGDSLC6A3 | |
| Hydrochloric Acid SCHEMBL9870098 | 0.94 | HTR2A (0.91) | HTR2ASLC18A2CYP3A4HPGDSLC6A3 | |
| SCHEMBL25837175 | 0.93 | HTR2A (0.89) | HTR2ASLC18A2CYP3A4HPGDSLC6A3 | |
| Butanserin SCHEMBL875652 | 0.93 | HTR2A (0.89) | HTR2ASLC18A2CYP3A4HPGDSLC6A3 | |
| Ketanserin SCHEMBL362930 | 0.93 | CYP2D6 (1.00) | HTR2ASLC18A2CYP3A4HPGDSLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4577245-A1 | DENDRIMER COMPOSITIONS FOR TARGETED DELIVERY OF PSYCHEDELIC THERAPEUTICS | The Johns Hopkins University (US) | 2025-07-02 | — | — | EP | claimed |
| WO-2024044756-A1 | DENDRIMER COMPOSITIONS FOR TARGETED DELIVERY OF PSYCHEDELIC THERAPEUTICS | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-02-29 | — | — | WO | claimed |
| US-10624887-B2 | Compositions of (-)-17-(cyclobutylmethyl)morphinan-3,14,-diol | RELMADA THERAPEUTICS, INC. (US) | 2020-04-21 | — | — | US | disclosed |
| WO-2018203664-A9 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NEUROLOGICAL DISORDERS OR CARDIOVASCULAR DISEASES, COMPRISING SRAGE-SECRETING STEM CELL | 주식회사 툴젠 | 2019-03-21 | — | — | WO | disclosed |
| EP-3432869-A1 | METHODS OF USING (2R, 6R)-HYDROXYNORKETAMINE AND (2S, 6S)-HYDROXYNORKETAMINE IN THE TREATMENT OF DEPRESSION, ANXIETY, ANHEDONIA, FATIGUE, SUICIDAL IDEATION, AND POST TRAUMATIC STRESS DISORDERS | THE UNITED STATES OF AMERICA, represented by the S (US) | 2019-01-30 | — | — | EP | disclosed |
| WO-2018203664-A2 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NEUROLOGICAL DISORDERS OR CARDIOVASCULAR DISEASES, COMPRISING SRAGE-SECRETING STEM CELL | 주식회사 툴젠 | 2018-11-08 | — | — | WO | disclosed |
| EP-3297620-A1 | KETAMINE TRANSDERMAL DELIVERY SYSTEM | Shenox Pharmaceuticals, LLC (US) | 2018-03-28 | — | — | EP | disclosed |
| EP-3240422-A1 | METHOD OF MAINTAINING THE ANTI-DEPRESSANT EFFECT OF KETAMINE WITH LITHIUM | Icahn School of Medicine at Mount Sinai (US) | 2017-11-08 | — | — | EP | disclosed |
| WO-2017165877-A1 | METHODS OF USING (2R, 6R)-HYDROXYNORKETAMINE AND (2S, 6S)-HYDROXYNORKETAMINE IN THE TREATMENT OF DEPRESSION, ANXIETY, ANHEDONIA, SUICIDAL IDEATION, AND POST TRAUMATIC STRESS DISORDERS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-09-28 | — | — | WO | disclosed |
| WO-2017003935-A1 | KETAMINE TRANSDERMAL DELIVERY SYSTEM | SHENOX PHARMACEUTICALS, LLC (US) | 2017-01-05 | — | — | WO | disclosed |
| US-20160235740-A1 | Compositions of (-)-17-(Cyclobutylmethyl)Morphinan-3,14,-Diol | RELMADA THERAPEUTICS, INC. (US) | 2016-08-18 | — | — | US | disclosed |
| WO-2016109427-A1 | METHOD OF MAINTAINING THE ANTI-DEPRESSANT EFFECT OF KETAMINE WITH LITHIUM | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2016-07-07 | — | — | WO | disclosed |
| EP-2861259-A1 | ANTI-PSMA ANTIBODIES CONJUGATED TO NUCLEAR RECEPTOR LIGAND POLYPEPTIDES | Ambrx, Inc. (US) | 2015-04-22 | — | — | EP | disclosed |
| WO-2013188740-A1 | ANTI-PSMA ANTIBODIES CONJUGATED TO NUCLEAR RECEPTOR LIGAND POLYPEPTIDES | AMBRX, INC. (US) | 2013-12-19 | — | — | WO | disclosed |
| EP-2475384-A1 | NEW VACCINE FORMULATIONS COMPRISING SAPONIN-CONTAINING ADJUVANTS | Merial Ltd. (US) | 2012-07-18 | — | — | EP | disclosed |
| WO-2011031850-A1 | NEW VACCINE FORMULATIONS COMPRISING SAPONIN-CONTAINING ADJUVANTS | MERIAL LIMITED (US) | 2011-03-17 | — | — | WO | disclosed |